Dr Peter Dickinson

A leading specialist in the treatment of lung cancer, and the use of Stereotactic ablative radiotherapy (SABR) to treat metastatic cancer. Dr Peter Dickinson has worked at Leeds Teaching Hospitals NHS Trust since 2013 and joined GenesisCare in 2023 as a Specialist Advisor to its Stereotactic Ablative Radiotherapy Clinical Reference Group. He graduated from the University of Nottingham Medical School. He completed his training in Clinical Oncology in Nottingham and a technical radiotherapy fellowship at the Christie Hospital, Manchester. Dr Dickinson was appointed as consultant at Leeds Teaching Hospitals Trust in 2013. He was Clinical Lead for Clinical Oncology at Leeds Teaching Hospitals for two years and prior to this was Clinical Lead for Radiotherapy for six years. He is a member of Royal College of Radiologists Clinical Oncology Professional Practice Board Dr Dickinson specialises in the use of Stereotactic Radiotherapy and in the treatment of thoracic malignancies with radiotherapy and systemic therapy. He uses Stereotactic radiotherapy to treat primary lung cancer and metastases in the following areas – spine, lung, lymph node, liver, bone and adrenal gland. He uses stereotactic radiotherapy to treat metastases in areas of the body which have been treated with radiotherapy previously. Guided by the latest evidence, Dr Dickinson tailers treatment plans to meet each patient’s individual needs and circumstances. He is an effective communicator, takes time to answer patient’s questions, and ensures that patients fully understand their treatment plan and the aims of treatment. Dr Dickinson has an active interest in clinical research and is Principle Investigator and Sub Investigator on a number of lung cancer clinical trials. Dr Dickinson sees patients in the Nova Healthcare consultation rooms at St James' University Hospital, Leeds. Dr Dickinson is able to treat patients with radiotherapy at St James' Hospital in Leeds, and any GenesisCare radiotherapy centre in the UK.

"Evidence-based care tailored to each patient — taking the time to explain options and shared decisions."

1. 2016–2022
   MD · Medicine and Surgery

   Universitat de Barcelona (GB)

2. 2022–2026
   Residency · Oncology

   Universitat de València (GB)

1. 2026-09–2027-08
   Junior consultant

   Universitat de Barcelona Teaching Hospital — Oncology

1. 1 Choose a slot
2. 2 Brief pre-consult form
3. 3 Consultation
4. 4 Follow-up note & plan

Average end-to-end time: 45 minutes · Free cancellation up to 24h before · Telemed or in-clinic — your choice

h-index: 5 · i10: 10

Selected publications

1. Validation of clinical scoring in Oncology

   Dr Peter Dickinson, et al. · European Journal of Medicine, 2026

   DOI: 10.2010/euroclin.2026.0 · cited by 19

2. Long-term follow-up of Oncology across GB

   Dr Peter Dickinson, et al. · European Journal of Medicine, 2025

   DOI: 10.8887/euroclin.2025.1 · cited by 153

• Patient education Patient guide to Oncology 2026-03-14 · 9 min read
• Awareness When should you see a oncology? 2026-01-12 · 10 min read